Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
5
×
new york blog main
new york top stories
san diego blog main
san diego top stories
5
×
san francisco blog main
san francisco top stories
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boulder/denver blog main
boulder/denver top stories
drugs
fda
national
cancer
clinical trials
deals
eli lilly
gene therapy
indiana blog main
indiana top stories
ipo
jefferies
roche
san francisco
startups
accelerator
What
big
5
×
companies
make
meeting
new
startup
week
admits
ago
aiming
ambys
american
approval
arguments
ash
bio
biotech
biotechs
blood
bosley's
bosley’s
bridge
bucks
cas
ceo
class
classes
combinator
commercialized
competitors
control
country
crime
crispr
deadly
deal
debuted
decades
departure
diego
Language
unset
Current search:
big
×
" national top stories "
×
" san diego top stories "
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?